NEW YORK, Oct. 21, 2022 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, PC, a nationally recognized shareholder rights law firm, is investigating potential claims against Spectrum Pharmaceuticals, Inc. SPPIF45 Training Holdings, Inc. FXLVPROG Holdings, Inc. PRGand UiPath, Inc. AWAY. Our investigations address whether these companies have violated federal securities laws and/or engaged in other illegal business practices. For more information on each case, see the link provided.

Spectrum Pharmaceuticals, Inc. SPPI

on September 22, 2022, Reuters reported that U.S. Food and Drug Administration advisors “voted against the recommendation of Spectrum Pharmaceuticals’ investigational drug for the treatment of patients with a form of non-small cell lung cancer, which has marginal efficacy, high toxicity, and lack of dose optimization. The panel’s decision was consistent with.” Information documents released Tuesday by the drug agency that raised concerns about the treatment’s effectiveness compared to existing drugs such as Daiichi Sankyo’s 4568.T Enhertu of AstraZeneca.”

As a result of this news, Spectrum’s stock price fell $0.207 per share, or 32.65%, to close at $0.427 per share on September 23, 2022.

For more information on Spectrum testing, see: https://bespc.com/cases/SPPI

F45 Training Holdings, Inc. FXLV

On or about July 15, 2021, F45 Training completed its initial public offering (“IPO”), selling 18.75 million shares at a price of $16.00 per share.

Then, on July 26, 2022, F45 issued a press release titled “F45 Training Announces Strategic Update”. In the press release, F45 Training provided an updated 2022 revenue guidance in the range of $120-130 million, well below the previous guidance of $255-275 million, citing ongoing macroeconomic uncertainty. The press release also revealed the departure of the company’s Chief Executive…